Luciferase Reporter Cancer Cell Lines
CAR-T cell-based therapeutics have emerged as a promising immunotherapy for treating specific leukemias, lymphomas, and myelomas. In this exciting approach to treating refractory cancers, T cells are isolated from a patient’s blood via apheresis.
- CAR-T cells are a new type of "living" therapeutic
- Harnesses the patient’s immune system to recognize specific tumor-associated antigens
- Redirects the engineered T cells to more specifically target tumor cells.
Click here to find out more: https://lifescience.invitro.com.au/resources/cellandgenetherapy/celltherapysolutions/immunecelltherapy/luciferase-reporter-cancer-cell-lines
